| Aug 12 |
Prelude Therapeutics GAAP EPS of -$0.46
|
| Aug 12 |
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jul 26 |
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
|
| Jul 10 |
Prelude and MSD partner to trial PRT3789 and Keytruda combination
|
| Jul 9 |
Prelude, Merck strike clinical trial collaboration and supply pact
|
| Jul 9 |
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
|
| Jun 20 |
Barclays cuts Prelude to underweight, cites lack of near-term catalysts
|
| Jun 20 |
Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls
|
| Jun 3 |
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
|
| May 30 |
Prelude Therapeutics files for $400M mixed securities shelf
|
